(Q43034283)

English

Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels

scientific article published in September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

Itoh Y

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Morita A

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nishioji K

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Narumi S

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Toyama T

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Daimon Y

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nakamura H

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kirishima T

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Okanoue T

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

341-348

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The scientific challenge of hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Antigenicities of Group I and II hepatitis C virus polypeptides--molecular basis of diagnosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Development of a quantitative PCR assay for monitoring HCV viraemia levels in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Liver infiltrating T lymphocytes express interferon gamma and inducible nitric oxide synthase in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00309.X

21 January 2018

Identifiers

10.1046/J.1365-2893.2001.00309.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43034283&oldid=2046618514"